Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Plus Therapeutics
Deal Size : $137.2 million
Deal Type : Licensing Agreement
Details : Plus Therapeutics closed its previously announced definitive agreement to license multiple rare cancer product candidates that includes, Rhenium-186-chelated NanoLiposome from NanoTx Therapeutics.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $0.4 million
May 11, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Plus Therapeutics
Deal Size : $137.2 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?